HEPA

Hepion Pharmaceuticals
HEPA

Overview Fund Activity
Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

26 hedge funds and large institutions have $2.2M invested in Hepion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
8
Reduced
8
Closed
1
Calls
$52K
Puts
$1K
Net Calls
+$51K
Net Calls Change
-$38K

Top Buyers

1
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$34.5K
2
Morgan Stanley
Morgan Stanley
New York
+$19K
3
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$5.66K
4
RJFSA
Raymond James Financial Services Advisors
Florida
+$5.48K
5
Renaissance Technologies
Renaissance Technologies
New York
+$4.21K

Top Sellers

1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$20.7K
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$20.7K
3
PAM
PVG Asset Management
Colorado
-$14.2K
4
VF
Virtu Financial
New York
-$13.4K
5
Citadel Advisors
Citadel Advisors
Florida
-$5.79K
Name Holding Trade Value Shares
Change 		Shares
Change %
Wells Fargo
26
Wells Fargo
California
$156 – – –
Bank of America
27
Bank of America
North Carolina
$54 – – –
S
28
SignatureFD
Georgia
$1 – – –
UBS Group
29
UBS Group
Switzerland
– -$5K -11 Closed
1
2